Other studies have indicated that after anti-PD-1 therapy, TIM-3 expression on T cells is increased in PD NSCLC patients, whereas TIM-3 expression on T cells is decreased in the SD group (34). The gene discussed is HAVCR2; the disease is non-small cell lung carcinoma.